PDK3 and metabolic disease: This approach allowed us to reveal the conserved pathogenic role of Upd3–JAK–STAT or IL-6–JAK–STAT signalling in cancer-associated metabolic disorder, highlighting a potential therapeutic strategy of targeting hepatic gluconeogenesis or PDK3 in IL-6-driven cancer cachexia.